Leukemia News and Research RSS Feed - Leukemia News and Research

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Metabolite in gut microbiome could improve outcomes after bone marrow transplant

Metabolite in gut microbiome could improve outcomes after bone marrow transplant

Could playing better defense make bone marrow transplants more successful? With this question in mind, researchers began looking at whether the trillions of little bugs and bacteria living in our gastrointestinal tract could be the key to playing defense. [More]
Four key genes govern growth, multiplication of blood stem cells

Four key genes govern growth, multiplication of blood stem cells

An important element in getting blood stem cells to multiply outside the body is to understand which of the approximately 20,000 genes in the human body control their growth. Now a research team at Lund University in Sweden has studied close to 15,000 of these genes alongside each other. [More]
Novel compound shows promise as potential treatment for acute myeloid leukemia

Novel compound shows promise as potential treatment for acute myeloid leukemia

A novel compound has shown promise in preclinical studies as a treatment for acute myeloid leukemia, more than doubling median days of survival even in a drug-resistant form of the disease. [More]
MRX-2843 treatment improves survival of acute myeloid leukemia patients

MRX-2843 treatment improves survival of acute myeloid leukemia patients

Acute myeloid leukemia (AML) is a cancer of myeloid stem cells that develops in both adult and pediatric populations. Mutations that cause hyperactivation of the FMS-like tyrosine kinase 3 (FLT3) are commonly found in AML, and several clinical trials are testing FLT3 inhibitors. [More]
CIRM approves $6.3 million grant to support research on novel stem cell-based therapy for ALS

CIRM approves $6.3 million grant to support research on novel stem cell-based therapy for ALS

The Independent Citizens Oversight Committee of the California Institute for Regenerative Medicine approved yesterday a $6.3 million grant to a research team from the University of California, San Diego School of Medicine and University of California, Davis to pursue a novel human embryonic stem cell-based therapy to rescue and restore neurons devastated by amyotrophic lateral sclerosis or ALS. [More]
Secondary non-Hodgkin's lymphoma a concern for CML patients using TKIs

Secondary non-Hodgkin's lymphoma a concern for CML patients using TKIs

Patients with chronic myeloid leukaemia who use the tyrosine kinase inhibitor imatinib may be three to four times more likely to develop non-Hodgkin's lymphoma than the general population, study findings indicate. [More]
Vascular events in CML may not be linked to TKI therapy

Vascular events in CML may not be linked to TKI therapy

The increased risk of vascular events observed among elderly patients with chronic myeloid leukaemia, compared with patients without cancer, may not be driven by tyrosine kinase inhibitor therapy, US researchers suggest. [More]
Coloring can help cancer patients cope with stress

Coloring can help cancer patients cope with stress

Sandy Gantt receives infusions of chemotherapy to treat her leukemia for hours on end, day after day. But she's found one thing that transports her from that reality to a less stressful place."Coloring is a nice, soothing distraction from treatment," she said, shading an intricate mandala design. "I get lost in it, and it gets me away from my worries." [More]
DelMar's VAL-083 receives FDA orphan drug designation for treatment of medulloblastoma

DelMar's VAL-083 receives FDA orphan drug designation for treatment of medulloblastoma

DelMar Pharmaceuticals, Inc., announced today that the FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation for its lead product candidate, VAL-083, in the treatment of medulloblastoma. [More]
Scientists find surprising link between iPS cell reprogramming, blood cell formation and cancer

Scientists find surprising link between iPS cell reprogramming, blood cell formation and cancer

The ability to reprogram cells has revolutionized stem cell research with major implications for almost all fields of modern biology. A decade ago Shinya Yamanaka described a procedure that revolutionized stem cell biology. Using a genetic trick that introduces a cocktail of four genes into cultured cells from human biopsies, he was able to generate induced pluripotent stem cells (iPS) from mature skin or blood cells [More]
STING agonists developed to induce cellular death in B cell malignancies

STING agonists developed to induce cellular death in B cell malignancies

In almost every mammalian cell, you will find the endoplasmic reticulum, a network of continuous membranes responsible for controlling metabolism as well as the folding, assembly and secretion of proteins. [More]
Hematopoietic reprogramming can lead to differentiated blood products for cell-replacement therapy

Hematopoietic reprogramming can lead to differentiated blood products for cell-replacement therapy

Building upon previous work, researchers at the Icahn School of Medicine at Mount Sinai identified cells in the embryos of mice that are precursors to blood stem cells or hematopoietic stem/progenitor cells. [More]
ACGT awards new research grants to take researchers to next level in cancer treatment

ACGT awards new research grants to take researchers to next level in cancer treatment

Alliance for Cancer Gene Therapy, the nation's only nonprofit dedicated exclusively to cell and gene therapies for cancer, is delighted to announce the recipients of its 2016 ACGT Young Investigator Grants. [More]
Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with IgG4-Related Disease (IgG4-RD). [More]
Leukemia researchers uncover protein that allows blood cancers to develop

Leukemia researchers uncover protein that allows blood cancers to develop

Walter and Eliza Hall Institute researchers have uncovered a protein that is key to the development of blood cancers caused by a common genetic error. [More]
RUVICA (ibrutinib) capsules approved for treatment-naïve CLL patients

RUVICA (ibrutinib) capsules approved for treatment-naïve CLL patients

The U.S. Food and Drug Administration has approved IMBRUVICA (ibrutinib) capsules for treatment-naïve patients with chronic lymphocytic leukemia (CLL). [More]
Rice university researchers uncover elusive lung cancer cells

Rice university researchers uncover elusive lung cancer cells

Researchers at Rice University and the University of Texas MD Anderson Cancer Center have uncovered a trick used by lung cancer cells to hide from the body's immune system. [More]
Researchers find Achilles' heel of acute lymphoblastic leukemia

Researchers find Achilles' heel of acute lymphoblastic leukemia

Researchers at The Ottawa Hospital and the University of Ottawa have found the Achilles' heel of one of the most aggressive forms of leukemia that affects both children and adults. They have also identified a possible new treatment that exploits this fatal weakness. [More]
Potential link between PLCD and ALL could offer new targets for cancer prevention research

Potential link between PLCD and ALL could offer new targets for cancer prevention research

A potential correlation between pre-labor cesarean delivery (PLCD) and acute lymphoblastic leukemia (ALL) could offer new targets for cancer prevention research, according to new research from the Masonic Cancer Center, University of Minnesota. [More]
EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

AbbVie, a global biopharmaceutical company, today announced the European Medicines Agency has granted Orphan Drug Designation to venetoclax, an investigational, oral B-cell lymphoma-2 (BCL-2) inhibitor, for the treatment of acute myeloid leukemia (AML). [More]
Advertisement